Celgosivir (hydrochloride)

Celgosivir hydrochloride (MBI 3253 hydrochloride; MDL 28574 hydrochloride; MX3253 hydrochloride) is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in in vitro assay.

Product Specifications

CAS Number

[141117-12-6]

Product Name Alternative

MBI 3253 (hydrochloride) ; MDL 28574 (hydrochloride) ; MX3253 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dengue Virus; Flavivirus; Glycosidase; HCV; HIV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Celgosivir-hydrochloride.html

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

O[C@@H]1[C@]2([H])[C@@H](O)[C@H](O)[C@@H](OC(CCC)=O)CN2CC1.Cl[H]

Molecular Formula

C12H22ClNO5

Molecular Weight

295.76

Precautions

H302, H315, H319, H335

References & Citations

[1]Taylor DL, et al. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoylcastanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother. 1994 Aug;38 (8) :1780-7.|[2]Whitby K, et al. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother. 2004 May;15 (3) :141-51.|[3]Watanabe S, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012 Oct;96 (1) :32-5.|[4]Rathore AP, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes andprotects against lethal challenge mouse model. Antiviral Res. 2011 Dec;92 (3) :453-60.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

HIV-1

Citation 01

J Virol. 2025 Mar 18;99 (3) :e0001825.|University of Pennsylvania. 2018 Dec.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

GTR14653308 1 Each

Standard gene synthesis [RFQ]

Ask

View Details

G2040-04-Biotin 100 µL

Glucagon, NT (Biotin) discontinued

Ask

View Details

44143011 1.0 µg DNA

SLC35E2 ORF Vector (Human) (pORF)

Ask

View Details

NBP2-74333R 0.1 mL

Mouse Monoclonal Spinesin Antibody (OTI4A11) [DyLight 550]

Ask

View Details